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Abstract
Background:  We previously reported that survivin-2B, a splicing variant of survivin, was
expressed in various types of tumors and that survivin-2B peptide might serve as a potent
immunogenic cancer vaccine. The objective of this study was to examine the toxicity of and to
clinically and immunologically evaluate survivin-2B peptide in a phase I clinical study for patients
with advanced or recurrent breast cancer.
Methods: We set up two protocols. In the first protocol, 10 patients were vaccinated with
escalating doses (0.1–1.0 mg) of survivin-2B peptide alone 4 times every 2 weeks. In the second
protocol, 4 patients were vaccinated with the peptide at a dose of 1.0 mg mixed with IFA 4 times
every 2 weeks.
Results: In the first protocol, no adverse events were observed during or after vaccination. In the
second protocol, two patients had induration at the injection site. One patient had general malaise
(grade 1), and another had general malaise (grade 1) and fever (grade 1). Peptide vaccination was
well tolerated in all patients. In the first protocol, tumor marker levels increased in 8 patients,
slightly decreased in 1 patient and were within the normal range during this clinical trial in 1 patient.
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With regard to tumor size, two patients were considered to have stable disease (SD).
Immunologically, in 3 of the 10 patients (30%), an increase of the peptide-specific CTL frequency
was detected. In the second protocol, an increase of the peptide-specific CTL frequency was
detected in all 4 patients (100%), although there were no significant beneficial clinical responses.
ELISPOT assay showed peptide-specific IFN-γ responses in 2 patients in whom the peptide-specific
CTL frequency in tetramer staining also was increased in both protocols.
Conclusion: This phase I clinical study revealed that survivin-2B peptide vaccination was well
tolerated. The vaccination with survivin-2B peptide mixed with IFA increased the frequency of
peptide-specific CTL more effectively than vaccination with the peptide alone, although neither
vaccination could induce efficient clinical responses. Considering the above, the addition of another
effectual adjuvant such as a cytokine, heat shock protein, etc. to the vaccination with survivin-2B
peptide mixed with IFA might induce improved immunological and clinical responses.
Background
The incidence of breast cancer has continuously increased
in Japan, similar to European countries and the USA,
whereas mortality from breast cancer has declined, indi-
cating improving survival because of the development of
early diagnosis [1-3]. However, metastatic recurrence still
occurs, and once the cancer has spread beyond the breast
and locoregional nodal areas it is felt to be incurable [4].
In the case of metastatic recurrence, the prevailing treat-
ment is systemic chemotherapy, which is fraught with var-
ious adverse effects. Thus, we considered the availability
of immunotherapy, which is generally reported to be safe,
for advanced or recurrent breast cancer.
Tumor cells express antigens that can be recognized by the
host's immune system. In the past decade, many antigenic
peptides, which can be recognized by CTLs, have been
identified [5-9]. As a result, clinical trials of peptide-based
immunotherapy for cancer have taken place. Melanoma
antigen peptides were the first to be tested in phase I and
phase II studies for active immunization of metastatic
melanoma patients [10,11]. Recently, there are reports of
clinical trials for various cancers, including colorectal can-
cer [12], esophageal cancer [13], pancreatic cancer [14],
among others. However, most clinical trials did not dem-
onstrate sufficient anti-tumor clinical responses. Thus, it is
necessary to establish peptide-based immunotherapy that
can induce sufficient clinical responses.
Survivin was initially isolated as one of the inhibitors of
the apoptosis protein family with only one baculovirus
inhibitor of apoptosis protein (IAP) repeat domain [15].
Survivin is aberrantly expressed in various cancer cells but
is undetectable in normal differentiated adult tissues, with
the exception of the testis, thymus and placenta. We have
previously reported that survivin-2B, a splicing variant of
survivin, is expressed in various tumor cell lines [16], and
the survivin-2B80-88 (AYACNTSTL) peptide derived from
the exon 2B-encoded region is recognized by CD8+ CTLs
in the context of HLA-A24 molecules [16]. In addition, we
recently reported further evidence that survivin-2B80-88
peptide might serve as a potent immunogenic cancer vac-
cine for various cancer patients [17]. In that report, we
demonstrated that overexpression of survivin was
detected in surgically resected primary tumor specimens
of most breast cancers in an immunohistochemical study.
In addition, HLA-A24/survivin-2B80-88 tetramer analysis
revealed that there were an increased number of CTL pre-
cursors in peripheral blood mononuclear cells (PBMCs),
and in vitro stimulation of PBMCs from 6 breast cancer
patients with survivin-2B80-88 peptide led to increases of
the CTL precursor frequency. Furthermore, CTLs specific
for this peptide were successfully induced in PBMCs from
all 7 HLA-A24+ patients (100%) with breast cancers and
exhibited cytotoxicity against HLA-A24+/survivin+ adeno-
carcinoma cells [17]. On the basis of these studies, we
started a phase I clinical study of vaccination with sur-
vivin-2B peptide for patients with advanced or recurrent
breast cancer.
Methods
Patient selection
The study protocol was approved by the Clinic Institu-
tional Ethical Review Board of the Medical Institute of
Bioregulation, Sapporo Medical University, Japan. All
patients gave informed consent before being enrolled.
Patients enrolled in this study were required to conform
to the following criteria: (1) to have histologically con-
firmed breast cancer, (2) to be HLA-A*2402 positive, (3)
to be survivin-positive in the carcinomatous lesions by
immunohistochemistry, (4) to be between 20 and 85
years old, (5) to be unresectable advanced cancer or recur-
rent cancer and (6) to have Eastern Cooperative Oncology
Group (ECOG) performance status between 0 and 3.
Exclusion criteria included (1) prior cancer therapy such
as chemotherapy, radiation therapy, steroid therapy, or
other immunotherapy within the past 4 weeks, (2) the
presence of other cancers that might influence the progno-
sis, (3) immunodeficiency or a history of splenectomy,
(4) severe cardiac insufficiency, acute infection, or hemat-Journal of Translational Medicine 2008, 6:24 http://www.translational-medicine.com/content/6/1/24
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opoietic failure, (5) ongoing breast-feeding and (6)
unsuitability for the trial based on clinical judgment. This
study was carried out at the Department of Surgery, Sap-
poro Medical University Primary Hospital from July 2003
through November 2005.
Peptide preparation
The peptide, survivin-2B80-88 with the sequence AYAC-
NTSTL, was prepared under good manufacturing practice
conditions by Multiple Peptide Systems (San Diego, CA).
The identity of the peptide was confirmed by mass spec-
trometry analysis, and the purity was shown to be more
than 98% as assessed by high pressure liquid chromatog-
raphy analysis.
The peptide was supplied as a freeze-dried, sterile white
powder. It was dissolved in 1.0 ml of physiological saline
(Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) and
stored at -80°C until just before use.
Incomplete Freund's Adjuvant (IFA) preparation
Montanide ISA 51 (SEPPIC Inc., NJ, USA) was used as
incomplete Freund's adjuvant (IFA).
Patient treatment
In this phase I clinical study, two protocols were used.
One was a basic protocol, namely, with survivin-2B pep-
tide alone, and the other used survivin-2B peptide mixed
with IFA. In this trial, the primary endpoint was safety.
The second endpoint was investigations about anti-tumor
effects and clinical and immunological monitoring.
In the first protocol, the vaccination schedule was as fol-
lows. Vaccinations with survivin-2B peptide were given
subcutaneously (s.c.) four times at 14-day intervals. To set
up a dose-escalation trial, the patients were separated into
the following two groups: in group 1 patients were vacci-
nated with 0.1 mg of the peptide and in group 2 patients
were vaccinated with 1.0 mg of the peptide. Each group
included five patients. Escalation to the next dose was
allowed if side effects did not exceed grade 3. If patients
whose disease was not far advanced hoped for continua-
tion of this peptide vaccination therapy, we vaccinated
them in the same manner after the fourth vaccination.
In the second protocol, survivin-2B peptide at a dose of 1
mg/1 ml and IFA at a dose of 1 ml were mixed immedi-
ately before vaccination. Then the patients were vacci-
nated subcutaneously (s.c.) four times at 14-day intervals.
Delayed-type hypersensitivity (DTH) skin test
A DTH skin test was performed at each vaccination. The
peptide (10 μg) solution in physiological saline (0.1 ml)
or physiological saline alone (0.1 ml) was separately
injected intradermally (i.d.) into the forearm opposite the
vaccination site. A positive reaction was defined as a more
than 4 mm diameter area of erythema and induration 48
hr after the injection.
Toxicity evaluation
Patients were examined closely for signs of toxicity during
and after vaccination. Adverse events were recorded using
the National Cancer Institute Common Toxicity Criteria
(NCI-CTC).
Clinical response evaluation
Physical examinations and hematological examinations
were conducted before and after each vaccination. Tumor
markers (CEA, CA15-3, NCC-ST-439, and ICTP) were
examined monthly.
Tumor size was evaluated by computed tomography (CT)
scans or MRI in comparison with the size before the first
vaccination and that after the fourth vaccination. A com-
plete response (CR) was defined as complete disappear-
ance of all measurable and evaluable disease. A partial
response (PR) was defined as a 30% decrease from the
baseline in the size of all measurable lesions (sum of max-
imal diameters). Progressive disease (PD) was defined as
an increase in the sum of maximal diameters by at least
20% or the appearance of new lesions. Stable disease (SD)
was defined as the absence of criteria matching those for
CR, PR, or PD. Patients who received less than four vacci-
nations were excluded from all evaluations in this study.
In vitro stimulation of PBMC
PBMCs were isolated from blood samples by Ficoll-Con-
ray density gradient centrifugation. Then they were frozen
and stored at -80°C. As needed, frozen PBMCs were
thawed and incubated in the presence of 30 μl/ml sur-
vivin-2B peptide in AIM-V medium containing 10%
human serum at room temperature. Next, interleukin-2
was added at a final concentration of 50 U/ml 1 hr, 2 days,
4 days and 6 days after the addition of the peptide. On day
7 of culture, the PBMCs were analyzed by tetramer stain-
ing and ELISPOT assay.
Tetramer staining
FITC-labeled HLA-A*2402-HIV peptide (RYLRDQQLL)
tetramer and PE-labeled HLA-A*2402-Survivin-2B80-88
peptide tetramer were purchased from MBL Inc.(Japan).
For flow cytometric analysis, PBMCs, which were stimu-
lated in vitro as above, were stained with the tetramers at
37°C for 20 min, followed by staining with FITC- or
PerCP-conjugated anti-CD8 mAb (Beckton Dickinson
Biosciences) at 4°C for 30 min. Cells were washed twice
with PBS before fixation in 1% formaldehyde. Flow cyto-
metric analysis was performed using FACSCalibur and
CellQuest software (BD Biosciences). The frequency ofJournal of Translational Medicine 2008, 6:24 http://www.translational-medicine.com/content/6/1/24
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CTL precursors was calculated as the number of tetramer-
positive cells divided by the number of CD8-positive cells.
ELISPOT assay
ELISPOT plates were coated sterilely overnight with an
IFN-γ capture antibody (Beckton Dickinson Biosciences)
at 4°C. The plates were then washed once and blocked
with AIM-V medium containing 10% human serum for 2
hr at room temperature. CD8-positive T cells separated
from patients' PBMCs (5 × 103 cells/well), which were
stimulated in vitro as above, were then added to each well
along with HLA-A24-transfected CIR cells (CIR-A24) (5 ×
104 cells/well), which had been preincubated with or
without survivin-2B80-88 peptide (10 μg/ml) and with an
HIV peptide as a negative control. After incubation in a
5% CO2 humidified chamber at 37°C for 24 hours, the
wells were washed vigorously five times with PBS and
incubated with a biotinylated anti-human IFN-γ antibody
and horseradish peroxidase-conjugated avidin. Spots were
visualized and analyzed using KS ELISPOT (Carl Zeiss,
Germany).
Results
Patient profiles
In the first protocol with survivin-2B peptide alone, 12
patients were initially enrolled in the study (Additional
file 1), but two (cases 7 and 10) discontinued halfway
through the protocol. One patient (case 7) had local
recurrence, brain and lung metastases from bilateral
breast cancer and was removed from the study after 3 vac-
cinations since new brain metastasis appeared and she
required radiation therapy. Another patient (case 10) had
lymph node metastases from right breast cancer. She was
removed from the study after 3 vaccinations because of
enlargement of lymph node metastases. Neither of the
treatment interruptions was due to adverse effects of the
vaccination. Ten patients received the complete regimen
including four vaccinations and were evaluated. They
were all women, whose average age was 49 years (range,
34–71).
In the second protocol with survivin-2B peptide mixed
with IFA, five patients were initially enrolled in the study
(Additional File 2), but one (case 2) discontinued halfway
through the protocol. This patient had lung and liver
metastases from right breast cancer and was removed
from the study after 3 vaccinations because of exacerbated
liver function resulting from advanced liver metastases. In
this protocol, there were no patients who dropped out
because of adverse events due to the peptide vaccination.
Four patients received the complete regimen including
four vaccinations and were evaluated. They were all
women, whose average age was 52 years (range, 36–71).
Safety
Peptide vaccination was well tolerated in all patients. In
patients vaccinated with the peptide alone, no adverse
events were observed during or after vaccination (Addi-
tional File 3). Of the patients vaccinated with the peptide
mixed with IFA, two (cases 1 and 3) had induration at the
injection site (Additional File 4). One (case 4) had general
malaise (grade 1) and one (case 5) had general malaise
(grade 1) and fever (grade 1). No other severe adverse
events were observed during or after vaccination.
Clinical responses
Table 3 summarizes the clinical outcomes for the 10
patients in the first protocol with survivin-2B peptide
alone. In all patients except two (cases 1 and 9), the tumor
marker levels were increased. In one patient (case 1), the
levels of CEA, CA15-3 and NCC-ST-439 were within the
normal range during this clinical trial. The level of ICTP
was decreased from 7.2 ng/ml just before the first vaccina-
tion to 5.5 ng/ml after the fourth vaccination. However,
this change was not considered a significant decrease. In
case 9, all tumor marker levels were within the normal
range during this clinical trial. As for tumor size, two
patients (cases 3 and 5) were considered to have SD. In
one patient (case 9) who had bone metastases, the area of
bone metastases did not increase in bone scintigraphy,
and new metastatic foci did not appear during this trial. In
this patient, although there was no aggravation of the clin-
ical condition, we could not estimate the clinical response
by our criteria because bone metastases were not able to
be evaluated in CT images. The other patients were con-
sidered to have progressive disease (PD). In this protocol,
if patients whose disease was not far advanced hoped for
the continuation of this peptide vaccination therapy, we
vaccinated them in the same manner after the fourth vac-
cination. There were 2 patients (cases 3 and 9) who were
vaccinated for more than one year. In case 3, with bone
and lymph node metastases, vaccination continued 42
times for 20 months (Fig. 1). For this period, new meta-
static foci did not appear and there was almost no increase
in the size of the metastatic lesions in this patient. Tumor
marker levels did not increase rapidly (Fig. 1). In addition,
she maintained good quality of life because there was no
adverse effect.
Table 4 summarizes the clinical outcomes for the 4
patients in the second protocol with survivin-2B peptide
mixed with IFA. In all patients, the tumor marker levels
were increased. As for tumor size, all patients were consid-
ered to have PD.
DTH skin test
A DTH skin test was performed at each vaccination and
assessed 48 hr later. A positive reaction was defined as ery-
thema and induration more than 4 mm in diameter. InJournal of Translational Medicine 2008, 6:24 http://www.translational-medicine.com/content/6/1/24
Page 5 of 11
(page number not for citation purposes)
the first protocol with survivin-2B peptide alone, 2 of the
10 patients (20%) exhibited a positive DTH reaction at
least once during the study. In the second protocol with
peptide mixed with IFA, a positive DTH reaction was
observed in 1 of the 4 patients (25%).
Tetramer staining assay and ELISPOT assay
To determine if the survivin-2B peptide vaccination could
bring about specific immune responses in the patients, we
analyzed the peptide-specific CTL frequency by using the
HLA-A24/peptide tetramer. The change of tetramer-posi-
tive CTL frequency was evaluated by comparison with that
before the first vaccination and that after the fourth vacci-
nation as follows: detected and undetected. Detected was
defined as an increase of twofold or more. Undetected was
defined as a less than twofold increase. In the first proto-
col with the peptide alone, a change was considered to be
detected in 3 patients (30%) (Table 3). On the other
hand, in the second protocol with peptide mixed with
IFA, it was considered to be detected in all 4 patients
(100%) (Table 4). In Figure 2, the peptide-specific CTL
frequency in the second protocol is indicated as the per-
centage of tetramer-positive CTL cells among CD8-posi-
tive T cells before the first vaccination and after the fourth
vaccination.
ELISPOT assay of CD8-positive T cells separated from the
patients' PBMCs showed peptide-specific IFN-γ responses
in 2 patients, one of whom (case 8) was in the first proto-
col while the other (case 5) was in the second protocol. To
be more precise, in case 5 in the second protocol, in the
wells that were preincubated without the survivin-2B pep-
tide and with the HIV peptide, spots were almost not vis-
ualized. On the other hand, in the wells that had been
preincubated with survivin-2B peptide, many spots were
visualized (Fig. 3). In these two patients, the peptide-spe-
cific CTL frequency was also increased by the vaccination
with survivin-2B peptide.
Discussion
Recently, a large number of tumor antigens and epitopes
recognized by CTLs have been identified, and reports of
clinical trials utilizing peptide vaccination are increasing
[10,18-20]. We demonstrated that survivin was expressed
in a large proportion of various cancer specimens, and the
survivin-2B-derived peptide could induce a CTL response
in the context of HLA-A24 [16,17]. In addition, we
showed an elevation in CTL precursor frequencies in
PBMCs of HLA-A24+ cancer patients by using an HLA-
A24/survivin-2B peptide tetramer. On the basis of the
above studies, we started a phase I clinical study of sur-
vivin-2B peptide vaccine therapy for patients with
advanced or recurrent colorectal cancer in 2003 [12]. In
The changes in tumor marker levels in case 3 in the first protocol Figure 1
The changes in tumor marker levels in case 3 in the first protocol. For case 3, with bone and lymph node metastases, 
vaccination continued 42 times for 20 months. In this period new metastatic foci did not appear and there was almost no 
increase in size of the metastatic lesions. Tumor marker levels did not increase rapidly.
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this study, we vaccinated patients with survivin-2B pep-
tide alone, and reported the safety of this peptide vaccina-
tion and the potency of anti-tumor effects induced by the
peptide vaccination. At that time, we started this phase I
clinical study of peptide vaccine therapy for patients with
advanced or recurrent breast cancer as well. In this study,
we vaccinated patients with not only survivin-2B peptide
alone but also survivin-2B mixed with IFA in order to
induce greater anti-tumor effects. We recently established
immunological monitoring methods using a tetramer
staining assay and ELISPOT assay. Thus, in this study, we
also conducted immunological monitoring using these
techniques.
Survivin is an ideal tumor-associated antigen expressed in
a broad variety of malignancies and recognized by specific
cytotoxic T cells [21]. The first survivin-derived peptides
were characterized in 2000 [22,23]. Subsequently, there
Tetramer staining before the first vaccination and after the fourth vaccination in the second protocol Figure 2
Tetramer staining before the first vaccination and after the fourth vaccination in the second protocol. FITC-
labeled HLA-A*2402-HIV peptide (RYLRDQQLL) tetramer and PE-labeled HLA-A*2402-Survivin-2B80-88 peptide tetramer 
were uesd. For flow cytometric analysis, PBMCs, which were stimulated in vitro, were stained with the tetramers at 37°C for 
20 min, followed by staining with FITC- or PerCP-conjugated anti-CD8 mAb (Beckton Dickinson Biosciences) at 4°C for 30 
min. Cells were washed twice with PBS before fixation in 1% formaldehyde. Flow cytometric analysis was performed using 
FACSCalibur and CellQuest software (BD Biosciences). The frequency of CTL precursors was calculated as the number of 
tetramer-positive cells divided by the number of CD8-positive cells. The peptide-specific CTL frequency is indicated as the per-
centage of tetramer-positive CTL cells among CD8-positive T cells before the first vaccination and after the fourth vaccination. 
The peptide-specific CTL frequency after the fourth vaccination (B) was compared with that before the first vaccination (A). In 
the second protocol with the peptide mixed with IFA, the peptide-specific CTL frequency was increased in all 4 patients 
(100%).
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have been many reports about survivin peptide responses.
Grube et al. [24] reported that HLA-A2.1-restricted sur-
vivin peptide induced CD8+ T cell reactivity in patients
with multiple myeloma. Andersen et al. [25] reported the
detection of HLA-A24 restricted and survivin peptide-spe-
cific CD8-positive cells by IFN-γ ELISPOT assay and per-
forin ELISPOT assay in patients with breast cancer,
melanoma and renal cancer. Abrogating the function of
survivin not only limits the proliferative potential and via-
bility of tumor cells directly [26], but also inhibits tumor
angiogenesis [27]. Xiang et al. [28] reported that a DNA
vaccine targeting survivin lead to eradication of pulmo-
nary metastases by a combinational effect inducing tumor
cell apoptosis and suppressing tumor angiogenesis in a
murine model. Thus, survivin is a suitable target for
immune therapy for cancer [26,29]. Recently, a number of
survivin epitopes restricted to several additional HLA-
molecules have been identified [22,25,29-34], and several
clinical trials of immunotherapy based on survivin-
derived peptides have been initiated. Wobser et al. [35]
reported complete remission of liver metastasis of pancre-
atic cancer under vaccination with an HLA-A2 restricted
survivin peptide. In addition, a phase I/II trial with HLA-
A1, -A2 and -B35 restricted survivin peptides for patients
with advanced cancer is ongoing. Fuessel et al. [27]
reported a phase I clinical trial for patients with prostate
cancer in which they evaluated a vaccination with DCs
loaded with five different prostate cancer-associated anti-
gens (survivin, prostate-specific antigen [PSA], prostate-
specific membrane antigen [PSMA], and prostein, tran-
sient receptor potential p8 [trp-p8]) and concluded that
the concept was safe and feasible. Besides the above-men-
tioned investigations, various clinical trials are ongoing
now.
At present, 4 splicing variants of survivin (survivin-ΔEx3,
survivin-2α, survivin-2B, and survivin-3B) have been
identified. Espinosa et al. [36] reported that the expres-
sion of survivin-ΔEx3 and survivin-2B was higher in cervi-
cal cancer samples. There is also a report that survivin-2B
was dominantly expressed in gastric cancer [37].
Futakuchi et al. [38] reported that the ratios of survivin-
2B/survivin and survivin-ΔEx3/survivin in malignant cer-
vical tissue samples were significantly higher than those in
normal cervical tissue templates. Moreover, the ratio of
survivin-2B/survivin was increased in patients with higher
stages and with pelvic lymph node metastasis. These
reports might support the idea that survivin-2B is the ideal
ELISPOT assay after the fourth vaccination of case 5 in the second protocol Figure 3
ELISPOT assay after the fourth vaccination of case 5 in the second protocol. In the wells that were preincubated 
without survivin-2B peptide (A) or with an HIV peptide (C), spots were almost not visualized. On the other hand, in the wells 
that were preincubated with survivin-2B peptide (B), many spots were visualized. These findings demonstrate that CD8-posi-
tive T cells separated from the patients' PBMCs had a peptide-specific IFN-γ response.
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target of immunotherapy for cancer patients [17,39],
especially for those with advanced or recurrent cancer. On
the other hand, Mahotka et al. [40] reported that the ratio
of survivin-2B/survivin was decreased in the late stages of
renal cell carcinoma. Yamada et al. [41] reported that
there was no significant difference in the ratio of survivin-
2B/survivin in malignant brain tumors and gliomas com-
pared with nonglioma. There is a hypothesis that the rele-
vant ratios of the survivin and splicing variants may
regulate the ultimate apoptotic activities of cancer cells
and determine their biological behaviours and responses
to apoptosis-inducing treatment [37,40]. Nevertheless,
the exact roles and expression of survivin splicing variants
and their interplay in various cancers are as yet unclear
because of the high complexity of its regulation [36,42].
We previously demonstrated that the expression of sur-
vivin-2B was detected in a variety of tumor cell lines but
not in normal tissues except in the thymus, although low
levels of survivin expression were detected by reverse tran-
scription-PCR analysis [16]. In addition, we reported that
survivin-2B-specific CTLs could be induced efficiently
from PBMCs of HLA-A24-positive survivin-positive cancer
patients [17]. As described above, we are sure that sur-
vivin-targeting immunotherapy with survivin-2B peptide
should be a reasonable strategy.
A dose-escalation trial was chosen to estimate a safe and
optimal dose in the first protocol with survivin-2B peptide
alone. We used 0.1 mg and 1.0 mg dosage groups, each
consisting of five patients. No adverse events were
observed in either group. In addition, for the patients
(cases 3 and case 9) who were vaccinated 42 times and 38
times respectively, adverse events were not observed dur-
ing or after the vaccination. Thus, we concluded that the
survivin-2B peptide vaccine was safe and could be repeat-
edly injected into patients without severe adverse events.
In comparison between patients who were vaccinated
with 0.1 mg and 1.0 mg of the peptide, there was almost
no difference in clinical responses. However, peptide-spe-
cific immune responses in tetramer staining and ELISPOT
assay were frequently induced in patients vaccinated with
1.0 mg of the peptide in comparison with patients vacci-
nated with 0.1 mg of the peptide. Therefore, we decided
that the optimal dose of the peptide was 1.0 mg. IFA has
sustained-release effect, which can enhance the anti-
tumor effect of the peptide injected subcutaneously. So, in
the second protocol which its purpose was to induce the
more effective anti-tumor effect by the survivin-2B pep-
tide, IFA was used mixed with 1.0 mg of the peptide. In
this protocol, two patients (cases 1 and 3) had induration.
This was due to IFA trapped in the subcutaneous lesion.
Patient 4 had general malaise (grade 1), and patient 5 had
general malaise (grade 1) and fever (grade 1). No other
severe adverse events were observed during or after vacci-
nation. Therefore, we concluded that the vaccine using
survivin-2B peptide mixed with IFA was safe, as was the
peptide alone.
Positive delayed-type hypersensitivity (DTH) reactions
were observed in 2 of the 10 patients (20.0%) in the first
protocol and in 1 of the 4 patients (25.0%) in the second
protocol at least once during the vaccination. Some
reports have suggested a positive correlation between
DTH and clinical [43] or immunological responses [44].
In this study, in case 5 in the first protocol a positive DTH
reaction was observed and the change of tumor size was
considered to indicate SD, while the tumor marker level
was considered to have increased, although immunologi-
cal responses were not induced. However, neither clinical
nor immunological responses were totally associated with
a positive DTH reaction in this study.
In the first protocol with survivin-2B peptide alone, none
of patients in the 0.1 mg peptide group had tetramer
response and that 3 of the 5 patients (30%) in the 1.0 mg
peptide group had increased the tetramer-specific CTL fre-
quency. On the other hand, in the second protocol with
survivin-2B peptide mixed with IFA, all patients had a sig-
nificant increase of the tetramer-positive CTL frequency.
These results might demonstrate that the addition of IFA
could enhance the immunological responses to the sur-
vivin-2B peptide. In addition, these findings might also
indicate that the addition of another effectual adjuvant
such as a cytokine, heat shock protein [45], etc. to the vac-
cination with survivin-2B peptide mixed with IFA could
more effectively enhance the immunological and clinical
responses to the peptide. At present a phaseII clinical
study of survivin-2B peptide vaccine therapy, in which the
peptide is combined with IFA and IFN-α, is ongoing in
our group.
In the second protocol with the peptide mixed with IFA,
although all patients had an increase of the tetramer-pos-
itive CTL frequency, only one patient had a peptide spe-
cific IFN-γ response in the ELISPOT assay. In tetramer
staining, the frequency of the peptide-specific CTL was
investigated. In the ELISPOT assay, the function of the
peptide-specific CTL was investigated. It is possible that
the peptide-specific CTL induced by the vaccination might
not function well due to immune escape mechanisms in
the effector phase. Thus, this might be one of the reasons
why the CTL response to the vaccination was not suffi-
cient to induce clinical responses. This also could imply a
dysfunction of the host immune system or an immuno-
suppressive effect of the tumor microenvironment,
including the down-regulation of HLA-class I molecules
on tumor cells. Therefore, we have recently begun to
investigate a novel strategy to overcome the immune
escape in peptide vaccine therapy.Journal of Translational Medicine 2008, 6:24 http://www.translational-medicine.com/content/6/1/24
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Conclusion
In conclusion, this phase I clinical study revealed that the
administration of not only survivin-2B peptide alone but
also the peptide in combination with IFA for patients with
advanced or recurrent breast cancer was well tolerated.
Vaccination with survivin-2B peptide mixed with IFA
increased the frequency of the peptide-specific CTL more
effectively than vaccination with the peptide alone,
although neither vaccination could induce an efficient
clinical response. Thus, the addition of IFA might enhance
the immunological response to the peptide vaccination.
Considering the above, the addition of another effectual
adjuvant such as a cytokine, heat shock protein [45], etc.
to the vaccine using survivin-2B peptide mixed with IFA
might induce improved immunological and clinical
responses.
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